The Support. Don’t Punish campaign documents global efforts to progress harm reduction and drug policy reform as part of the 2020 Global Day of Action.

EHRA highlights ten case studies of harm reduction delivery during the pandemic situation.

HRI and IDPC discuss some of the current and emerging challenges specifically faced by people detained for drug offences and people in detention who use drugs.

Baltazar et al. shed light on the positive impact of access to drop-in centres and related services on the health of people who use drugs.

Plotko et al. found that, by and large, drug education for young people in the region remains anchored in the 'just say no' paradigm.

The EMCDDA provides an overview of the pandemic's impact in drug markets, service provision and people who use drugs.

The Council of the European Union approves the regional bloc's new Strategy, based on supply reduction, demand reduction and addressing drug-related harm.

The American Medical Association calls for an expansion of harm reduction efforts to tackle the overdose crisis.

The John Hopkins Bloomberg School of Public Health calls for increased attention and resources to curb the impact of the COVID-19 pandemic on the overdose crisis.

The Penington Institute explores the impact and success of the 2020 International Overdose Awareness Day.

The EMCDDA discusses the debates around the distribution and sale of low-THC cannabis products in Europe.

Conectas, IDPC, and INNPD provide input to the Committee on Economic, Social and Cultural Rights focusing on the serious violation of the rights to health of people who use drugs in Brazil.

IDPC and a coalition of NGOs provide recommendations to ensure that Nepalese national drug policies respect human rights and fundamental freedoms.

Miovský et al. suggest that the sustainability of harm reduction services in the region has been negatively affected by an under-investment in their institutionalisation.

Thomas D. Brothers et al. examine the encouraging metrics hospitals show in treating those with opioid dependencies and their positive impact after treatment has ended.

Niklas Karlsson et al. suggest delays in uptake and scale-up of harm reduction in Sweden could inform other countries' experiences toward implementing services.

ARASA documents funding and related obstacles to the regional HIV response.

Despite substantial, and welcomed, changes in the INCB's approach to human rights, reticences remain and point to structural conflicts between drug policy and human rights within the UN system.

Mainline provides a practical guide, developed with activists and practitioners, on supporting the involvement of peers in harm reduction work.

The EU Civil Society Forum on Drugs assesses the health of civil society engagement at the European level, providing guiding principles and examples of good practice.